Randomized comparison of 1-hour topical method vs. amoxycillin plus omeprazole for eradication of Helicobacter pylori in duodenal ulcer patients

Aliment Pharmacol Ther. 1998 Jan;12(1):69-75. doi: 10.1046/j.1365-2036.1998.00273.x.

Abstract

Background: A novel 1-h topical method eradicated Helicobacter pylori in 96% of dyspeptic patients. The eradication rate of amoxycillin/omeprazole therapy varies from 0 to 93%.

Aim: To compare both methods in patients with endoscopically proven duodenal ulcer.

Methods: Eighty patients (59 males, 21 females; median age 43 years) were randomized into two therapeutic groups. The first group (group A) was treated with a 6-week course of ranitidine 300 mg/day, then omeprazole 20 mg b.d. with pronase 36000 units/day for 2 days, followed by 1-h topical therapy with a solution of bismuth, metronidazole, amoxycillin and pronase. The second group (group B) consisted of patients treated with omeprazole 20 mg b.d. and amoxycillin 2 g/day for 2 weeks, followed by a 4-week course of ranitidine 300 mg/day. Eradication of H. pylori was assessed by urease test, histology, a polymerase chain reaction and a 13C-urea breath test, all of which were performed 4 weeks after discontinuation of the antibacterial treatment.

Results: Eradication rates in groups A and B were 2.5% and 35% in an intention-to-treat analysis, respectively. Side-effects were encountered in 40.5% and 12.5% of subjects in groups A and B, respectively. Treatment tolerance was rated as poor by 54% of patients in group A and 2.5% of patients in group B.

Conclusions: Both treatment regimens, the 1-h topical method and amoxycillin with omeprazole, have low eradication rates in patients with duodenal ulcer. In addition, the topical treatment is characterized by a high rate of side-effects and poor tolerance. Based on the results of our study, neither method can be recommended for eradication of H. pylori in patients with duodenal ulcer.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Amoxicillin / administration & dosage
  • Amoxicillin / therapeutic use*
  • Anti-Ulcer Agents / administration & dosage
  • Anti-Ulcer Agents / therapeutic use*
  • Bismuth / administration & dosage
  • Bismuth / therapeutic use
  • Clinical Protocols
  • Drug Therapy, Combination
  • Duodenal Ulcer / drug therapy*
  • Duodenal Ulcer / microbiology
  • Female
  • Helicobacter pylori / chemistry
  • Helicobacter pylori / drug effects*
  • Humans
  • Intubation, Gastrointestinal
  • Male
  • Metronidazole / administration & dosage
  • Metronidazole / therapeutic use
  • Middle Aged
  • Omeprazole / administration & dosage
  • Omeprazole / therapeutic use*
  • Penicillins / administration & dosage
  • Penicillins / therapeutic use*
  • Pronase / administration & dosage
  • Pronase / therapeutic use
  • Ranitidine / administration & dosage
  • Ranitidine / therapeutic use

Substances

  • Anti-Ulcer Agents
  • Penicillins
  • Metronidazole
  • Amoxicillin
  • Ranitidine
  • Pronase
  • Omeprazole
  • Bismuth